Wave Life Sciences (WVE) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic pipeline and clinical updates

• Focused on advancing oligonucleotide and RNA medicine platforms, leveraging over a decade of chemistry optimization and human clinical genetics.

• Clinical data for Inhibin βE siRNA in obesity showed promising fat loss, especially visceral fat, with preservation of lean mass at three months; further data from 240 mg (six months) and 400 mg (three months) cohorts expected soon.

• Accelerating Phase 2a studies to include higher BMI and comorbid patients, with plans to initiate this phase in the first half of the year.

• RNA editing program for alpha-1 antitrypsin deficiency demonstrated robust protein correction and is positioned for regulatory engagement and potential accelerated approval.

• Early discovery efforts include bifunctional modalities for simultaneous knockdown and editing, and expanding delivery to adipose and kidney tissues.

Clinical insights and regulatory strategy

• Inhibin βE siRNA therapy targets meaningful fat reduction, especially visceral fat, while preserving muscle, addressing key needs in obesity management.

• Maintenance potential highlighted: once or twice yearly dosing could sustain weight loss and improve compliance compared to current therapies.

• Phase 2a studies will assess effects in higher BMI and comorbid populations, with MRI imaging to evaluate liver fat reduction.

• Regulatory pathway for obesity and MASH indications will emphasize both weight loss and body composition improvements, aiming for differentiated labeling.

• For alpha-1 antitrypsin deficiency, biomarker-driven registration and confirmatory studies are planned, with potential to expand the market via genetic testing.

Market positioning and scalability

• Once or twice yearly subcutaneous dosing offers a significant advantage in accessibility and scalability for large patient populations.

• Manufacturing innovations and improved synthesis methods are reducing costs and enabling large-scale production.

• Distinct mechanism of action and body composition benefits may support premium pricing and broad adoption in obesity and related indications.

• Strategic interest from industry partners spans monotherapy, combination, and maintenance settings for obesity treatment.

• Bifunctional and dual-targeting approaches are expected to drive future pipeline expansion and cost efficiencies.